About Enhancer
| Enhancer ID: | E_01_0501 |
| Species: | human |
| Position : | chr12:100470925-100472925   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Non alcoholic fatty liver disease (nafld), inflammation |
| Pubmed ID: | 29743187 |
| Enhancer experiment: | Migration assay,Transient transfection,gene expression analysis,immunostaining, |
| Enhancer experiment description: | In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases. |
About Target gene
| Target gene : | LTB |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases.;In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases. |
About TF
| TF name : | NR1H4 |
| TF experiment: | Migration assay,Transient transfection,gene expression analysis,immunostaining, |
| TF experiment description: | In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases.;In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases. |
About Function
| Enhancer function : | In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| NR1H4 | Endogenous sterols | reactome | 22 |
| NR1H4 | Nuclear Receptor transcription pathway | reactome | 51 |
| NR1H4 | PPARA activates gene expression | reactome | 113 |
| NR1H4 | Recycling of bile acids and salts | reactome | 15 |
| NR1H4 | RXR and RAR heterodimerization with other nuclear receptor | pid | 26 |
| NR1H4 | Synthesis of bile acids and bile salts | reactome | 7 |
| NR1H4 | Synthesis of bile acids and bile salts via 27-hydroxycholesterol | reactome | 15 |
| NR1H4 | Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | reactome | 24 |
| NR1H4 | Hs_Drug_Induction_of_Bile_Acid_Pathway_WP2289_88593 | wikipathways | 9 |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene